Yang DH - Search Results

1

Pacritinib for myelofibrosis in adults with thrombocytopenia.

Yang DH, Lu Q, Zhu Z, Huang G, Young K. Yang DH, et al. Drugs Today (Barc). 2022 Dec;58(12):577-589. doi: 10.1358/dot.2022.58.12.3474538. Drugs Today (Barc). 2022. PMID: 36651066 Review.

2

The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. Ding PR, et al. Among authors: yang dh. PLoS One. 2011 Apr 28;6(4):e19329. doi: 10.1371/journal.pone.0019329. PLoS One. 2011. PMID: 21552528 Free PMC article.

3

Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.

Liu K, Cui JJ, Zhan Y, Ouyang QY, Lu QS, Yang DH, Li XP, Yin JY. Liu K, et al. Among authors: yang dh. Mol Cancer. 2022 Apr 11;21(1):98. doi: 10.1186/s12943-022-01561-5. Mol Cancer. 2022. PMID: 35410257 Free PMC article. Review.

4

The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.

Zhang H, Patel A, Wang YJ, Zhang YK, Kathawala RJ, Qiu LH, Patel BA, Huang LH, Shukla S, Yang DH, Ambudkar SV, Fu LW, Chen ZS. Zhang H, et al. Among authors: yang dh. Mol Cancer Ther. 2017 Jun;16(6):1021-1030. doi: 10.1158/1535-7163.MCT-16-0511. Epub 2017 Mar 6. Mol Cancer Ther. 2017. PMID: 28265007 Free PMC article.

5

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.

Cui Q, Cai CY, Wang JQ, Zhang S, Gupta P, Ji N, Yang Y, Dong X, Yang DH, Chen ZS. Cui Q, et al. Among authors: yang dh, yang y. Int J Mol Sci. 2019 Aug 22;20(17):4095. doi: 10.3390/ijms20174095. Int J Mol Sci. 2019. PMID: 31443367 Free PMC article.

6

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.

Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS. Gupta P, et al. Among authors: yang dh. Cancer Lett. 2020 Mar 1;472:132-141. doi: 10.1016/j.canlet.2019.11.040. Epub 2019 Dec 11. Cancer Lett. 2020. PMID: 31837444

7

A novel approach for relapsed/refractory FLT3^mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.

Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX. Li KX, et al. Among authors: yang dh. Mol Cancer. 2022 Mar 4;21(1):66. doi: 10.1186/s12943-022-01541-9. Mol Cancer. 2022. PMID: 35246156 Free PMC article.

8

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.

Zhang WJ, Li Y, Wei MN, Chen Y, Qiu JG, Jiang QW, Yang Y, Zheng DW, Qin WM, Huang JR, Wang K, Zhang WJ, Wang YJ, Yang DH, Chen ZS, Shi Z. Zhang WJ, et al. Among authors: yang dh, yang y. Cancer Lett. 2017 Feb 1;386:100-109. doi: 10.1016/j.canlet.2016.11.011. Epub 2016 Nov 15. Cancer Lett. 2017. PMID: 27864115

9

Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.

Wei LY, Wu ZX, Yang Y, Zhao M, Ma XY, Li JS, Yang DH, Chen ZS, Fan YF. Wei LY, et al. Among authors: yang dh, yang y. Exp Cell Res. 2020 Mar 15;388(2):111858. doi: 10.1016/j.yexcr.2020.111858. Epub 2020 Jan 20. Exp Cell Res. 2020. PMID: 31972220

10

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, Chen ZS. Li W, et al. Among authors: yang dh. Drug Resist Updat. 2016 Jul;27:14-29. doi: 10.1016/j.drup.2016.05.001. Epub 2016 May 13. Drug Resist Updat. 2016. PMID: 27449595 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,678 results

Search Page

Filters